| Kathryn Thompson, | |
|
75 Hickle St, Uniontown, PA 15401-4350 | |
| (724) 438-9762 | |
| Not Available |
| Full Name | Kathryn Thompson |
|---|---|
| Gender | Female |
| Speciality | Respiratory Therapist, Certified - General Care |
| Location | 75 Hickle St, Uniontown, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093188567 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn Thompson, 75 Hickle St, Uniontown, PA 15401-4350 Ph: (724) 438-9762 | Kathryn Thompson, 75 Hickle St, Uniontown, PA 15401-4350 Ph: (724) 438-9762 |
News Archive
According to a new study on cases of scarlet fever and other Streptococcus A infections in England and Wales, the recent rise in cases is due to a newly identified strain. This accounted for the great increase in the number of cases of scarlet fever that occurred in 2014. The last such outbreak was way back in the 1960s.
Bristol-Myers Squibb Company today announced that it has signed an agreement to sell its global diabetes business that was part of its collaboration with AstraZeneca. Under terms of the agreement, AstraZeneca will make an upfront payment of $2.7 billion to Bristol-Myers Squibb, with potential regulatory- and sales-based milestone payments of up to $1.4 billion and will make royalty payments based on net sales through 2025.
Sanofi-aventis reported today new one-year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis (RMS). Study results demonstrated an improvement in outcomes, with a consistent safety profile with the data from a previous Phase II monotherapy study, in patients treated with interferon beta (IFN-[BETA]) - a standard therapy in RMS - and receiving teriflunomide 7mg or 14mg, compared with patients treated with IFN-[BETA] and receiving oral placebo.
FDA does not have adequate resources to inspect foreign companies that manufacture medications or medication ingredients, and current funding levels for the agency will not address the issue, according to a Government Accountability Office report presented on Tuesday at a hearing of the House Energy and Commerce Oversight and Investigations Subcommittee, the Newark Star-Ledger reports.
› Verified 8 days ago